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Exercise Therapy and the Additional Effect of Supervision on Exercise
Therapy in Patients with Intermittent Claudication. Systematic Review
of Randomised Controlled Trials
Wind J., Koelemay M.J.W. Eur J Vasc Endovasc Surg 2007;34:1-9.
Objective: To review the evidence for the effectiveness of exercise
therapy and to estimate the additional effect of supervision on exercise
therapy in patients with intermittent claudication.
Materials and methods: A systematic review was performed of all
randomised controlled trials (RCTs) comparing supervised exercise therapy
to unsupervised exercise regimens or observation in patients with intermit-
tent claudication. Main endpoints were pain free walking distance (PWD)
and absolute walking distance (AWD). Quality assessment and data extrac-
tion were performed independently by two observers.
Results: Fifteen manuscripts, published between 1990 and May 2006,
were eligible for analysis, evaluating 761 patients. In the studies comparing
supervised exercise to standard care the weighted mean difference in pain
free walking distance (PWD) and absolute walking distance (AWD) was
81.3 meters (95% CI; 35.5–127.1) and 155.8 meters (95% CI;
80.8–230.7), respectively. In the studies comparing supervised to unsuper-
vised exercise therapy, the weighted mean difference in PWD and AWD was
143.8 meters (95% CI; 5.8–281.8) and 250.4 meters (95% CI; 192.4-
308.5).
Conclusion: Exercise therapy increases the PWD and AWD in patients
with intermittent claudication. Supervised exercise therapy increases the
PWD and AWD more than standard care. However, the additional value of
supervision over unsupervised exercise regimens needs further clarification.
C-Reactive Protein (CRP) as a Marker in Peripheral Vascular Disease
Abdellaoui A., Al-Khaffaf H. Eur J Vasc Endovasc Surg 2007;34:18-22.
Objective: To review the role of CRP as a marker for the prediction of
development of Peripheral Vascular Disease (PVD) and as a prognostic
indicator.
Methods: Search of the Cochrane Vascular Group Control Trials
Register, Medline and Embase for all published studies on the role of CRP
as a marker in peripheral vascular disease was undertaken.13 prospective
studies were found.
Results: 12 of the 13 prospective studies showed a strong association
between CRP and PVD. Three population studies involving 16561 people,
over a period of 6.5 to 12 years, revealed that high CRP levels approximately
tripled the risk of developing PVD, independently of all other risk factors.
Three case-control studies found that hsCRP was much higher in patients
with PVD. Four other studies, which covered 2337 people, demonstrated
that CRP levels were associated inversely with lower ankle brachial pressure
index. One study conducted on 384 people failed to show a link between
hsCRP and progression of ABPI. Two further small studies showed that
raised pre and post intervention hsCRP were associated with restenosis after
angioplasty.
Conclusions: CRP appears to be a strong predictor and marker of
severity of PVD and also may predict the risk of restenosis after angio-
plasty.
Is Infrainguinal Bypass Grafting Successful Following Failed
Angioplasty?
Sandford R.M., Bown M.J., Sayers R.D., London J.N., Naylor A.R., Mc-
Carthy M.J. Eur J Vasc Endovasc Surg 2007;34:29-34.
Objectives:Angioplasty is often used in the management of lower limb
ischaemia and can reduce the need for infrainguinal bypass in some patients.
There is an associated failure rate with this technique and bypass surgery is
often used in this situation as a secondary limb salvage procedure. We aimed
to evaluate the outcome of infrainguinal bypass grafting following failed
attempt at angioplasty.
Methods: All cases of infrainguinal bypass at a single centre over a
seven year period were identified and notes reviewed. Cases were divided
into four groups according to their indication for surgery; acute ischaemia,
chronic critical ischaemia, failed angioplasty and an ‘other’ group including
aneurysmal disease and claudicants. The failed angioplasty group was com-
pared with the other three groups. Survival analysis was performed using
Kaplan Meier curves and groups compared in terms of long term patency
and survival.
Results: Primary patency was 61.2% in the failed angioplasty group at
12 months compared with 60.6% in the other groups (P1.11). There was
also no significant difference in primary patency at 60 months (50% vs 40.6%,
P0.26). Survival at 12 months was also comparable between the groups
(failed angioplasty group 74.2% compared with 77.3% in the other groups,
P0.662) as was 60 months survival (33.3% and 35.4% respectively,
P0.166).
Discussion: In this study, outcome of infrainguinal bypass following
failed angioplasty was comparable to outcome of surgery performed for
another indication. This paper supports the use of distal bypass surgery for
limb salvage in cases where minimal access techniques have failed.
Dacron or PTFE for Above-knee Femoropopliteal Bypass. A Multi-
center Randomised Study
Jensen L.P., Lepäntalo M., Fossdal J.E., Røder O.C., Jensen B.S., Madsen
M.S., Grenager O., Fasting H., Myhre H.O., Bækgaard N., Nielsen O.M.,
Helgstrand U., Schroeder T.V. Eur J Vasc Endovasc Surg 2007;34:44-49.
Objectives: To compare polytetrafluorethylene (PTFE) and polyester
grafts (Dacron) for above knee femoropopliteal bypass.
Design: Multicenter randomised clinical trial.
Material andMethods: 427 patients were randomised between 6 mm
Dacron (Uni-Graft®, B. Braun Melsungen AG, 34212 Melsungen, Ger-
many) and PTFE (Goretex®, W. L. Gore & Ass. Inc., Newark DE 19711,
USA) above-knee femoropopliteal bypass grafts within 13 centres in Den-
mark (n261), Norway (n113) & Finland (n53) between 1993 and
1998. Fourteen (3%) patients were excluded, leaving 413 patients with 208
Dacron and 205 PTFE grafts for analysis. Age, gender, indication (claudi-
cation: 65%), run-off (2 or 3 vessels: 76%), diabetes (17%) and hypertension
(31%) as well as cerebrovascular (9%) and cardiac (33%) risks were evenly
distributed. Patients were followed postoperatively at 1, 12 and 24 months.
Patency assessment was based on ankle-brachial pressures or imaging in case
of doubt.
Results: The two-year primary patency rates for Dacron and PTFE
were 70% and 57% (p0.02), whereas the secondary patency rates were 76%
and 65% (p0.04), respectively. Primary patency at two years was signifi-
cantly influenced by the number of patent crural vessels (two or three 67%,
one 50%, p0.01). Amputations at two years, major in 4% and minor in 3%,
30-days mortality and complications (wound infections: 3% and other
wound complications: 13%) occurred equally frequent in both groups. At
two years, patients treated for critical limb ischemia had a major amputation
more often than patients operated on for intermittent claudication, 10 and 3
respectively (p0.003), and had higher mortality rates, 20% and 8% respec-
tively (p0.001).
Conclusion: This trial confirms that Dacron is at least as durable as
PTFE for above-knee bypass procedures, and might even be superior.
High-risk and Low-risk Screening for Abdominal Aortic Aneurysm
Both Reduce Aneurysm-related Mortality. A Stratified Analysis from a
Single-centre Randomised Screening Trial
Lindholt J.S., Juul S., Henneberg E.W. Eur J Vasc Endovasc Surg 2007;34:
53-58.
Background: Cardiovascular diseases and chronic obstructive pul-
monary disease (COPD) are both associated with abdominal aortic
aneurysms (AAA). The aim of this study was therefore to analyse whether
screening for AAA could be restricted to men with such diseases (high
risk group).
Methods: Before the date of randomisation of a population screen-
ing trial of 12,639 64–73-year-old males, all discharge diagnoses from
the National Patient Registry concerning AAA-related diseases were
merged with the screening results on attendance, AAA prevalence, and
AAA-related mortality and overall mortality. Differences in proportions
were compared by Chi square tests and differences in mortality by Cox
regression analyses.
Results: The attendance rate was 78.8% and 6.7% had an AAA in the
high risk group compared to 75.8% attendance (P0.001) and 2.9%
(P0.001) in the remaining population. Cumulatively, screening of only
high risk men with would have required 72.9% (95% C.I.: 72.3–74.5%)
fewer screening invitations, would have discovered 46.1% (95% C.I.: 38.9–
53.4%) of the AAA cases diagnosed and prevented 46.7% (95% C.I.: 28.3–
65.7%) of the AAA-related deaths. However, screening decreased AAA-
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